1 |
GlaxoSmithKline
|
1041 |
Registration: 14.8%
Summary results: 13.5%
Clinical study reports: 10.3%
Individual patient data: 13.5%
|
2 |
LEO Pharma
|
1030 |
Registration: 10%
Summary results: 18.8%
Clinical study reports: 12.5%
Individual patient data: 10.3%
|
3 |
Takeda
|
969 |
Registration: 15.6%
Summary results: 15.8%
Clinical study reports: 7.6%
Individual patient data: 9.5%
|
4 |
Pfizer
|
892 |
Registration: 15.6%
Summary results: 8.3%
Clinical study reports: 12%
Individual patient data: 8.8%
|
5 |
Novartis
|
884.5 |
Registration: 16.8%
Summary results: 18%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
6 |
Novo Nordisk
|
867 |
Registration: 15.6%
Summary results: 9%
Clinical study reports: 9%
Individual patient data: 9.8%
|
7 |
Boehringer Ingelheim
|
819 |
Registration: 16.8%
Summary results: 10.5%
Clinical study reports: 8.4%
Individual patient data: 5.3%
|
8 |
Amgen
|
704 |
Registration: 13.2%
Summary results: 13.9%
Clinical study reports: 5%
Individual patient data: 3.1%
|
9 |
Merck & Co.
|
676 |
Registration: 13.2%
Summary results: 5.8%
Clinical study reports: 6.6%
Individual patient data: 8.3%
|
10 |
AbbVie
|
658 |
Registration: 14.8%
Summary results: 6.8%
Clinical study reports: 1.8%
Individual patient data: 9.5%
|
11 |
Bayer
|
631.5 |
Registration: 15.4%
Summary results: 6.8%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
12 |
Eli Lilly
|
629 |
Registration: 11.1%
Summary results: 7%
Clinical study reports: 6.6%
Individual patient data: 6.8%
|
13 |
Bristol-Myers Squibb
|
626 |
Registration: 10%
Summary results: 6%
Clinical study reports: 6.8%
Individual patient data: 8.5%
|
14 |
Merck Serono
|
612 |
Registration: 10.8%
Summary results: 6.8%
Clinical study reports: 5.8%
Individual patient data: 7.2%
|
15 |
Johnson & Johnson
|
588 |
Registration: 14.4%
Summary results: 3.8%
Clinical study reports: 5%
Individual patient data: 6.3%
|
16 |
Astellas
|
574 |
Registration: 10.4%
Summary results: 4.3%
Clinical study reports: 5.8%
Individual patient data: 8.3%
|
17 |
Otsuka
|
518 |
Registration: 10%
Summary results: 7.5%
Clinical study reports: 1.4%
Individual patient data: 7%
|
18 |
AstraZeneca
|
513 |
Registration: 12.4%
Summary results: 9.3%
Clinical study reports: 0%
Individual patient data: 4%
|
19 |
Daiichi Sankyo
|
511 |
Registration: 10%
Summary results: 2.5%
Clinical study reports: 5.8%
Individual patient data: 7.2%
|
20 |
UCB
|
508.5 |
Registration: 14.4%
Summary results: 6.5%
Clinical study reports: 1.4%
Individual patient data: 3.1%
|
21 |
Roche
|
506.5 |
Registration: 0%
Summary results: 9%
Clinical study reports: 11.2%
Individual patient data: 5.1%
|
22 |
Eisai
|
490.5 |
Registration: 10%
Summary results: 1.9%
Clinical study reports: 5.4%
Individual patient data: 7.2%
|
23 |
Biogen
|
478.5 |
Registration: 10%
Summary results: 4.5%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
24 |
Ipsen
|
468 |
Registration: 14.4%
Summary results: 9%
Clinical study reports: 0%
Individual patient data: 0%
|
25 |
Sanofi
|
463.5 |
Registration: 10%
Summary results: 3.8%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
26 |
Lundbeck
|
447 |
Registration: 10.8%
Summary results: 2.1%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
27 |
Almirall
|
413 |
Registration: 14.4%
Summary results: 6.3%
Clinical study reports: 0%
Individual patient data: 0%
|
28 |
Celgene
|
393.5 |
Registration: 10%
Summary results: 0.3%
Clinical study reports: 5.8%
Individual patient data: 3.6%
|
29 |
PhRMA et al 2005
|
342.5 |
Registration: 14%
Summary results: 3.1%
Clinical study reports: 0%
Individual patient data: 0%
|
30 |
PhRMA et al 2009
|
300.5 |
Registration: 12.4%
Summary results: 2.6%
Clinical study reports: 0%
Individual patient data: 0%
|
31 |
Orion Pharma
|
300 |
Registration: 10%
Summary results: 1.9%
Clinical study reports: 0%
Individual patient data: 3.1%
|
32 |
Servier
|
296 |
Registration: 14.8%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
33 |
PhRMA "Conduct" 2014
|
275 |
Registration: 10%
Summary results: 3.8%
Clinical study reports: 0%
Individual patient data: 0%
|
34 |
Menarini
|
262.5 |
Registration: 10%
Summary results: 3.1%
Clinical study reports: 0%
Individual patient data: 0%
|
35 |
Grunenthal
|
234 |
Registration: 0%
Summary results: 0%
Clinical study reports: 5.2%
Individual patient data: 6.5%
|
36 |
ViiV Healthcare
|
225 |
Registration: 0%
Summary results: 0%
Clinical study reports: 5%
Individual patient data: 6.3%
|
37 |
EFPIA/PhRMA "Sharing" 2013
|
175.5 |
Registration: 0%
Summary results: 0%
Clinical study reports: 5.4%
Individual patient data: 3.4%
|
38 |
Purdue Pharma
|
62.5 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 3.1%
|
39 |
Medtronic
|
37.5 |
Registration: 0%
Summary results: 1.9%
Clinical study reports: 0%
Individual patient data: 0%
|
40 |
Abbott
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
41 |
Alkermes
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
42 |
Dainippon Sumitomo
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
43 |
Esteve
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
44 |
Gilead
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
45 |
Sigma-Tau
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|
46 |
Valeant
|
0 |
Registration: 0%
Summary results: 0%
Clinical study reports: 0%
Individual patient data: 0%
|